12 completed, 2 terminated, 1 withdrawn. 9 Phase 1, 5 Phase 2, 2 Phase 3.
| Phase | Trials | Status |
|---|---|---|
| Phase 1 | 9 | Completed 8, Withdrawn 1 |
| Phase 2 | 5 | Completed 3, Terminated 1, Withdrawn 1 |
| Phase 3 | 2 | Completed 1, Terminated 1 |
Follow AT-527: new trials by email Literature Review of AT-527 trials Research Report on AT-527
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| A Phase 2, Safety and Efficacy of Bemnifosbuvir (BEM) and Ruzasvir (RZR) in Subjects With Chronic HCV Bemnifosbuvir, Ruzasvir - Chronic Hepatitis C Virus, Hepatitis C, Chronic | Phase 2 | Completed | Atea Pharmaceuticals, Inc. | 275 | 2023-05-30 | 2025-10-21 |
| The Study of Bemnifosbuvir in Healthy Japanese Subjects Bemnifosbuvir (BEM) - Healthy Volunteer Study | Phase 1 | Completed | Atea Pharmaceuticals, Inc. | 14 | 2023-04-26 | 2023-06-15 |
| Study of Bemnifosbuvir on Cardiac Repolarization in Healthy Subjects Bemnifosbuvir (BEM), Placebo, Moxifloxacin - Healthy Volunteer Study | Phase 1 | Completed | Atea Pharmaceuticals, Inc. | 35 | 2023-04-25 | 2023-06-15 |
| Drug-drug Interaction Study of Ruzasvir and Bemnifosbuvir Cohort 1 BEM + Ruzasvir, Cohort 2 Ruzasvir + BEM - Healthy Volunteer Study | Phase 1 | Completed | Atea Pharmaceuticals, Inc. | 32 | 2023-01-30 | 2023-06-01 |
| Study of Bemnifosbuvir in Subjects With Normal and Impaired Hepatic Function Bemnifosbuvir (BEM) - Healthy Volunteer, Hepatic Impairment | Phase 1 | Completed | Atea Pharmaceuticals, Inc. | 39 | 2023-01-30 | 2024-07-31 |
| SUNRISE-3: Efficacy and Safety of Bemnifosbuvir in High-Risk Outpatients With COVID-19 Bemnifosbuvir (BEM), Placebo - Severe Acute Respiratory Syndrome Coronavirus 2 (SARS CoV 2 Infection), COVID-19 | Phase 3 | Completed | Atea Pharmaceuticals, Inc. | 2285 | 2022-11-25 | 2025-06-13 |
| Study of AT-527 in Subjects With Normal and Impaired Renal Function AT-527, AT-527 and Probenecid - Healthy Volunteer, Renal Impairment | Phase 1 | Completed | Atea Pharmaceuticals, Inc. | 36 | 2022-10-17 | 2024-07-31 |
| Study of AT-527 in Healthy Subjects Under Fasting Conditions or With a Meal AT-527 fasted, Placebo Comparator fasted, AT-527 fed - Healthy Volunteer Study | Phase 1 | Completed | Atea Pharmaceuticals, Inc. | 136 | 2022-02-22 | 2022-10-18 |
| Study of AT-777 in Healthy Subjects and AT-777 in Combination With AT-527 in HCV-Infected Subjects AT-777, Placebo, AT-527 - Hepatitis C, Hepatitis C, Chronic | Phase 1 / Phase 2 | Withdrawn | Atea Pharmaceuticals, Inc. | 2021-10-01 | 2022-06-08 | |
| Study to Evaluate the Effects of RO7496998 (AT-527) in Non-Hospitalized Adult and Adolescent Participants With Mild or Moderate COVID-19 RO7496998, Placebo - COVID-19 | Phase 3 | Terminated | Hoffmann-La Roche | 216 | 2021-04-28 | 2024-01-05 |
| Bronchopulmonary PK of AT-527 (R07496998) AT-527 - Healthy Volunteer Study | Phase 1 | Completed | Atea Pharmaceuticals, Inc. | 24 | 2021-04-25 | 2022-02-25 |
| Study to Evaluate the Effects of AT-527 in Non-Hospitalized Adult Patients With Mild or Moderate COVID-19 AT-527, Placebo - COVID-19 | Phase 2 | Completed | Hoffmann-La Roche | 104 | 2021-02-03 | 2022-10-26 |
| Safety and Efficacy of AT-527 in Subjects With Moderate Coronavirus Disease (COVID-19) in a Hospital Setting AT-527, Placebo - COVID-19 | Phase 2 | Terminated | Atea Pharmaceuticals, Inc. | 83 | 2020-05-26 | 2023-03-09 |
| Study of AT-527 in Combination With Daclatasvir in Subjects With Hepatitis C Virus (HCV) Infection AT-527, Daclatasvir - Hepatitis C, Hepatitis C, Chronic | Phase 2 | Completed | Atea Pharmaceuticals, Inc. | 10 | 2019-06-20 | 2020-05-04 |
| Study of AT-527 in Healthy and HCV-Infected Subjects AT-527, Placebo Comparator - Chronic Hepatitis C, Hepatitis C | Phase 1 | Completed | Atea Pharmaceuticals, Inc. | 88 | 2017-07-06 | 2020-02-18 |
COVID-19 (4) · Hepatitis C (4) · Hepatitis C, Chronic (4) · Flaviviridae Infections (1) · Hepatitis, Viral, Human (1) · Liver Cirrhosis (1) · Liver Diseases (1) · Renal Insufficiency (1)
Atea Pharmaceuticals, Inc. (13) · Hoffmann-La Roche (2)
Canada (7) · Belgium (5) · United States (5) · Brazil (4) · Moldova (4) · Romania (4) · Argentina (3) · South Africa (3) · Spain (3) · Turkey (Türkiye) (3) · United Kingdom (3) · Germany (2) · India (2) · Japan (2) · Latvia (2)
Xiao-Jian Zhou, PhD (2) · Xiao-Jian Zhou (1)
PMID 31570394, PMID 37338393, PMID 37928891, PMID 38051993
2019 (2)